1 / 6

Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation

SPORTIF V Trial. Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation . Presented at American Heart Association Scientific Sessions 2003 Presented By Jonathan L Halperin, M.D. SPORTIF V Trial.

varen
Télécharger la présentation

Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SPORTIF V Trial Stroke Prevention Using the Oral Direct Thrombin Inhibitor Ximelagatran in Patients With Nonvalvular Atrial Fibrillation Presented at American Heart Association Scientific Sessions 2003 Presented By Jonathan L Halperin, M.D.

  2. SPORTIF V Trial 3,922 patients with nonvalvular AF and risk factors for stroke (previous stroke, hypertension, or CHF) Randomized Double-blind to: • Ximelagatran (36 mg bid) • A novel, oral direct thrombin inhibitor ximelagatran • (n = 1,960) • Warfarin • Target INR 2.0-3.0 • (n = 1,962) • Endpoints (mean follow-up 20 months): • Primary – All strokes (ischemic or hemorrhagic) and systemic embolic events, based on an intention-to-treat analysis for non-inferiority • Secondary – Composite of death, stroke, systemic embolism, and MI; and safety variables, specifically bleeding and liver enzyme elevations AHA 2003 Late Breaking Trials

  3. SPORTIF V Trial: Strokes (ischemic or hemorrhagic) and Systemic Embolic Events Intent-to-Treat Absolute 0.45% annual  in ximelagatran arm (95% CI -0.13-1.03, p=0.13) Met non-inferiority hypothesis In As-Treated Analysis: • Absolute 0.55% annual  in ximelagatran arm • 95% CI -0.06-1.16 • p=0.089 Event Rate (% per year) Warfarin Ximelagatran AHA 2003 Late Breaking Trials

  4. SPORTIF V Trial: Bleeding Events p=NS p=NS Event Rate (% per year) ICH Major Bleed AHA 2003 Late Breaking Trials

  5. SPORTIF V Trial: Liver Enzyme Elevation ALT >3x ULN p<0.001 Warfarin Ximelagatran AHA 2003 Late Breaking Trials

  6. SPORTIF V Trial: Combined Major Adverse EventsOn-Treatment Analysis Primary Events + Major Bleeding + Death p=0.527 Event Rate (% per year) Warfarin Ximelagatran AHA 2003 Late Breaking Trials

More Related